DelMar Pharmaceuticals (DMPI) Given $11.16 Consensus Price Target by Brokerages

Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) have received an average broker rating score of 1.50 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.

Analysts have set a twelve-month consensus price objective of $11.16 for the company and are expecting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 106 out of 265 based on the ratings given to its competitors.

DelMar Pharmaceuticals stock opened at $0.97 on Friday. The firm has a market cap of $21.27 million, a price-to-earnings ratio of -1.31 and a beta of 1.46. DelMar Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $1.01.

DelMar Pharmaceuticals (NASDAQ:DMPI) last released its quarterly earnings results on Tuesday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.03). sell-side analysts forecast that DelMar Pharmaceuticals will post -0.46 EPS for the current fiscal year.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply